Skip to content

WenYang SanHan Formula for the Treatment of Cold-Damp Obstruction Type Painful Diabetic Peripheral Neuropathy (PDPN): A Randomized, Multicenter, Prospective Clinical Study

A Randomized, Multicenter, Prospective Clinical Study on the Treatment of Cold-Damp Obstruction Type Painful Diabetic Peripheral Neuropathy (PDPN) Patients with Wenyang Sanhan Decoction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000982
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-04-23
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painful Diabetic Peripheral Neuropathy

Interventions

Experimental Group:Wenyang Sanhan Formula

Sponsors

Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age: 20-80 years; 2) Meets diagnostic criteria for diabetes; 3) Meets diagnostic criteria for diabetic peripheral neuropathy; 4) Meets diagnostic criteria for PDPN; 5) Matches TCM syndrome differentiation of cold-dampness obstruction; 6) Pain score requirements: BPI-DPN pain score = 4 or VAS score = 4; 7) Voluntary participation with signed informed consent; 8) Permitted concomitant medications/treatments.

Exclusion criteria

Exclusion criteria: 1) Does not meet inclusion criteria; 2) Peripheral neuropathy caused by other factors (trauma, infection, etc.); 3) Surgery within 1 month prior to screening; 4) Recent infections or diabetic ketoacidosis; 5) Severe complications (foot infections, cardiovascular diseases, etc.); 6) Infectious diseases (syphilis, HIV, hepatitis B) or coagulation disorders; 7) Severe psychiatric conditions affecting pain assessment; 8) Pregnancy/lactation or unwillingness to use contraception; 9) Allergy to study medication components; 10) Substance abuse history; 11) Participation in other clinical trials; 12) Previous trial participation within 3 months; 13) Investigator-determined unsuitability; 14) Prohibited concomitant medications/treatments.

Design outcomes

Primary

MeasureTime frame
Diabetic Peripheral Neuropathy Pain Scale;

Secondary

MeasureTime frame
Visual Analog Scale;Toronto Clinical Scoring System;Daily Sleep Interference Diary;Patient Global Impression of Change;Nerve Conduction Velocity Comparison;Traditional Chinese Medicine Syndrome Scale;

Countries

China

Contacts

Public ContactChuangpeng Shen

Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital

shenchuangpeng@gzucm.edu.cn13570301311

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026